Genetron Holdings Limited
Index- P/E- EPS (ttm)-0.80 Insider Own16.03% Shs Outstand92.27M Perf Week-2.01%
Market Cap125.12M Forward P/E- EPS next Y-0.39 Insider Trans0.00% Shs Float29.16M Perf Month-33.94%
Income-73.10M PEG- EPS next Q- Inst Own20.90% Short Float5.06% Perf Quarter-57.56%
Sales78.40M P/S1.60 EPS this Y-88.10% Inst Trans-0.51% Short Ratio4.65 Perf Half Y-88.85%
Book/sh2.21 P/B0.66 EPS next Y48.70% ROA-18.00% Target Price4.76 Perf Year-92.33%
Cash/sh1.72 P/C0.85 EPS next 5Y- ROE-21.20% 52W Range1.25 - 23.76 Perf YTD-76.07%
Dividend- P/FCF- EPS past 5Y- ROI-14.80% 52W High-93.86% Beta-
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin63.50% 52W Low16.80% ATR0.18
Employees799 Current Ratio6.50 Sales Q/Q36.20% Oper. Margin-67.10% RSI (14)33.37 Volatility16.03% 11.43%
OptionableNo Debt/Eq0.06 EPS Q/Q14.20% Profit Margin-61.20% Rel Volume0.47 Prev Close1.49
ShortableYes LT Debt/Eq0.02 EarningsMar 29 BMO Payout- Avg Volume317.16K Price1.46
Recom1.70 SMA20-17.86% SMA50-36.32% SMA200-81.88% Volume149,965 Change-2.01%
Jul-14-20Initiated Canaccord Genuity Buy $19
Jul-14-20Initiated BTIG Research Buy $20
May-03-22 09:11AM  
Apr-19-22 06:00AM  
Apr-08-22 06:00AM  
Apr-07-22 06:00AM  
Mar-29-22 07:26AM  
Mar-21-22 08:00AM  
Mar-09-22 04:05PM  
Feb-10-22 03:06AM  
Jan-31-22 08:00AM  
Jan-10-22 06:00AM  
Dec-13-21 01:30AM  
Nov-30-21 12:57PM  
Nov-29-21 10:00PM  
Nov-16-21 05:00AM  
Nov-15-21 08:00AM  
Nov-08-21 05:00AM  
Nov-04-21 04:05PM  
Nov-03-21 02:00AM  
Oct-28-21 12:38AM  
Oct-23-21 09:45AM  
Oct-22-21 07:00AM  
Oct-06-21 06:13AM  
Sep-27-21 10:25AM  
Sep-16-21 06:00AM  
Sep-03-21 11:07AM  
Aug-30-21 06:00AM  
Aug-24-21 07:51AM  
Aug-23-21 05:00PM  
Aug-11-21 08:00AM  
Jul-29-21 04:35AM  
Jul-26-21 06:00AM  
Jul-13-21 08:30AM  
Jul-06-21 04:30AM  
Jul-01-21 10:00PM  
Jun-04-21 06:00AM  
May-24-21 06:45AM  
May-20-21 06:16AM  
May-13-21 06:20AM  
May-10-21 07:00AM  
May-03-21 05:00PM  
Apr-22-21 06:25PM  
Apr-13-21 01:31AM  
Apr-01-21 06:00PM  
Mar-27-21 04:10AM  
Mar-25-21 06:47AM  
Mar-24-21 05:00PM  
Mar-17-21 04:30PM  
Mar-15-21 06:24AM  
Mar-04-21 05:00PM  
Feb-09-21 07:00AM  
Jan-27-21 05:00AM  
Jan-13-21 06:30AM  
Jan-07-21 09:32AM  
Jan-06-21 04:40AM  
Dec-20-20 03:04AM  
Dec-11-20 10:38PM  
Nov-27-20 08:00AM  
Nov-20-20 06:00AM  
Nov-19-20 09:53AM  
Nov-12-20 05:30AM  
Nov-09-20 06:30AM  
Oct-29-20 08:00AM  
Oct-26-20 08:00AM  
Oct-22-20 06:00AM  
Sep-30-20 08:11AM  
Sep-25-20 06:00AM  
Sep-18-20 06:00AM  
Sep-08-20 04:15PM  
Aug-29-20 10:32AM  
Aug-06-20 06:30AM  
Jul-29-20 04:39PM  
Jul-27-20 04:30PM  
Jun-30-20 08:55AM  
Jun-19-20 08:45AM  
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.